Literature DB >> 36271152

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase.

Sandra Huber1, Torsten Haferlach1, Manja Meggendorfer1, Stephan Hutter1, Gregor Hoermann1, Constance Baer1, Wolfgang Kern1, Claudia Haferlach2.   

Abstract

Entities:  

Year:  2022        PMID： 36271152     DOI： 10.1038/s41375-022-01734-7

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  1 in total

1.  SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.

Authors:  Abhishek A Mangaonkar; Terra L Lasho; Christy Finke; Rhett P Ketterling; Kaaren K Reichard; Kristen McCullough; Naseema Gangat; Aref Al-Kali; Kebede H Begna; William H Hogan; Mark R Litzow; Hassan Alkhateeb; Mithun Shah; Animesh Pardanani; Ayalew Tefferi; Najla H Al Ali; Chetasi Talati; David Sallman; Eric Padron; Rami Komrokji; Mrinal M Patnaik
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 11.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.